Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.
Stocks · News reference
Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.
8-K filing — Avalyn Pharma Inc. (AVLN)
Filed: 2026-08-12 AccNo: 0001193125-26-345807 Size: 295 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits